Antiviral Drug Discovery To Address the COVID-19 Pandemic

The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that em...

Descripción completa

Detalles Bibliográficos
Autor principal: Richman, Douglas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520600/
https://www.ncbi.nlm.nih.gov/pubmed/32978312
http://dx.doi.org/10.1128/mBio.02134-20
_version_ 1783587807863767040
author Richman, Douglas D.
author_facet Richman, Douglas D.
author_sort Richman, Douglas D.
collection PubMed
description The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M(pro)) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
format Online
Article
Text
id pubmed-7520600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-75206002020-10-02 Antiviral Drug Discovery To Address the COVID-19 Pandemic Richman, Douglas D. mBio Commentary The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M(pro)) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic. American Society for Microbiology 2020-09-25 /pmc/articles/PMC7520600/ /pubmed/32978312 http://dx.doi.org/10.1128/mBio.02134-20 Text en Copyright © 2020 Richman. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Richman, Douglas D.
Antiviral Drug Discovery To Address the COVID-19 Pandemic
title Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_full Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_fullStr Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_full_unstemmed Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_short Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_sort antiviral drug discovery to address the covid-19 pandemic
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520600/
https://www.ncbi.nlm.nih.gov/pubmed/32978312
http://dx.doi.org/10.1128/mBio.02134-20
work_keys_str_mv AT richmandouglasd antiviraldrugdiscoverytoaddressthecovid19pandemic

Ejemplares similares